GB2283021B - A recombinant poxviral vaccine for canine distemper - Google Patents

A recombinant poxviral vaccine for canine distemper

Info

Publication number
GB2283021B
GB2283021B GB9500214A GB9500214A GB2283021B GB 2283021 B GB2283021 B GB 2283021B GB 9500214 A GB9500214 A GB 9500214A GB 9500214 A GB9500214 A GB 9500214A GB 2283021 B GB2283021 B GB 2283021B
Authority
GB
United Kingdom
Prior art keywords
canine distemper
recombinant poxviral
vaccine
poxviral vaccine
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB9500214A
Other languages
English (en)
Other versions
GB2283021A (en
GB9500214D0 (en
Inventor
Enzo Paoletti
Jill Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virogenetics Corp
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of GB9500214D0 publication Critical patent/GB9500214D0/en
Publication of GB2283021A publication Critical patent/GB2283021A/en
Application granted granted Critical
Publication of GB2283021B publication Critical patent/GB2283021B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB9500214A 1990-11-20 1991-11-20 A recombinant poxviral vaccine for canine distemper Expired - Lifetime GB2283021B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62161490A 1990-11-20 1990-11-20
US77686791A 1991-10-22 1991-10-22
GB9309414A GB2264949B (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Publications (3)

Publication Number Publication Date
GB9500214D0 GB9500214D0 (en) 1995-03-01
GB2283021A GB2283021A (en) 1995-04-26
GB2283021B true GB2283021B (en) 1995-07-05

Family

ID=27089007

Family Applications (2)

Application Number Title Priority Date Filing Date
GB9500214A Expired - Lifetime GB2283021B (en) 1990-11-20 1991-11-20 A recombinant poxviral vaccine for canine distemper
GB9309414A Expired - Lifetime GB2264949B (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9309414A Expired - Lifetime GB2264949B (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Country Status (12)

Country Link
JP (2) JP3617668B2 (enExample)
AU (1) AU1253892A (enExample)
BE (1) BE1005908A5 (enExample)
CA (1) CA2096633A1 (enExample)
CH (1) CH683921A5 (enExample)
DE (2) DE4192786B4 (enExample)
FR (1) FR2669346B1 (enExample)
GB (2) GB2283021B (enExample)
IE (2) IE68404B1 (enExample)
IT (1) IT1252687B (enExample)
NL (2) NL195058C (enExample)
WO (1) WO1992008789A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
AU674491B2 (en) * 1991-03-20 1997-01-02 Virogenetics Corporation Recombinant poxvirus malaria vaccine
DE69233080T2 (de) * 1991-06-14 2004-04-15 Connaught Technology Corp., Greenville Rekombinanter hiv-spezifischer impfstoff aus poxviru
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CN1089370C (zh) * 1994-12-08 2002-08-21 中国预防医学科学研究院病毒学研究所 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒
AU2118997A (en) * 1996-02-05 1997-08-22 Johns Hopkins University, The Measles immunization by dna transcription unit inoculation
WO1998050047A1 (en) 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1095948A1 (en) * 1999-10-28 2001-05-02 Universitätsklinikum Freiburg Idiotype vaccines
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003429A1 (en) * 1987-08-28 1989-04-20 Health Research Inc. Recombinant avipox virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617715B1 (fr) * 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JPH01218590A (ja) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003429A1 (en) * 1987-08-28 1989-04-20 Health Research Inc. Recombinant avipox virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc.Natl.Acad.Sci. USA, Vol 85, 1988, pages 1252-1256 *

Also Published As

Publication number Publication date
DE4192786B4 (de) 2006-08-24
NL195095C (nl) 2004-01-21
FR2669346A1 (fr) 1992-05-22
GB2283021A (en) 1995-04-26
ITMI913092A0 (it) 1991-11-20
NL9120026A (nl) 1993-09-01
NL195058C (nl) 2003-07-01
GB9500214D0 (en) 1995-03-01
DE4192786T1 (de) 1994-01-13
ITMI913092A1 (it) 1993-05-20
JPH06502996A (ja) 1994-04-07
AU1253892A (en) 1992-06-11
IE71643B1 (en) 1997-02-26
CH683921A5 (fr) 1994-06-15
IE913960A1 (en) 1992-05-20
GB9309414D0 (en) 1993-07-14
NL9900036A (nl) 2003-10-01
BE1005908A5 (fr) 1994-03-08
IT1252687B (it) 1995-06-23
WO1992008789A1 (en) 1992-05-29
JP3824619B2 (ja) 2006-09-20
GB2264949A (en) 1993-09-15
IE68404B1 (en) 1996-06-12
CA2096633A1 (en) 1992-05-21
GB2264949B (en) 1995-07-05
JP2005040129A (ja) 2005-02-17
JP3617668B2 (ja) 2005-02-09
FR2669346B1 (fr) 1995-07-21

Similar Documents

Publication Publication Date Title
AU2371692A (en) Recombinant hepatitis a virus vaccine
GB9303023D0 (en) Flavivirus recombinant poxvirus vaccine
ZA922011B (en) Vaccine
EP0383833A4 (en) Vaccines for malaria
GB8907914D0 (en) Vaccine preparation
ZA91534B (en) Vaccines
FI903852A7 (fi) Menetelmä rekombinanttisen alayksikkörokotteen valmistamiseksi pseudor abiesinfektiota vastaan
HU9500417D0 (en) Hepatitis a vaccine
GB2264949B (en) Measles virus recombinant poxvirus vaccine
HU9300010D0 (en) Glycoprotein vaccine named ehv-4
GB8921470D0 (en) Vaccines
GB9201139D0 (en) Synthetic peptides for a rubella vaccine
US5084271B1 (en) Vaccine for equine herpesvirus
ZA903142B (en) Canine corona virus vaccine
AU4489896A (en) Avian recombinant live vaccine
EP0533263A3 (en) A multivalent hepatitis b virus vaccine
GB9202933D0 (en) Vaccines
ZA896372B (en) Vaccine
EP0912193A4 (en) Vaccine for the prevention of streptococcal endocarditis
ZA924670B (en) Ccv vaccine
AU3751093A (en) Recombinant antigen containing in its sequence a heterologous immunostimulatory domain-use as a vaccine
GB9213882D0 (en) Live modified equine herpesvirus-4 vaccine
GB8828523D0 (en) St-lt recombinant antigen vaccines
EP0453452A4 (en) Vaccine
GB9104903D0 (en) Viral vaccines

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20111119